GenMont Biotech Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
For the nine months, sales was TWD 262.53 million compared to TWD 308.61 million a year ago. Net income was TWD 43.13 million compared to TWD 68.91 million a year ago. Basic earnings per share was TWD 0.5 compared to TWD 0.8 a year ago. Diluted earnings per share was TWD 0.5 compared to TWD 0.79 a year ago.